In Vitro PDX Models
In addition to more than 260 commercial human tumor cell lines, we currently have over 75 proprietary cell lines derived from our PDX models, each with selected clinical data and comprehensive molecular data for the originating tumor, and which have been characterized by their sensitivity for up to 240 reference agents.
By using tumor cell lines derived from our portfolio of PDX models, we retain characteristics such as expression and mutation profiles, which enables us to offer “matched pairs” of xenografts and corresponding cell lines. This allows you to use the same models for in vitro, ex vivo and in vivo efficacy studies.
In Vitro Tumor Cell Line Screening
We offer fixed in vitro PDX model screening panels for the most cost-and time-efficient studies such as:
- Solid tumor histotypes
- Hematological cell lines
- Asian cancer cell lines
We also offer customized panels of up to 100 cell types.
Our 2D assays can be used in a variety of ways:
- Assessment of potency and selectivity
- Identification of mode of action via COMPARE analysis
- Administration of combination studies
- Analysis of multidrug resistance
Integrating In Vitro and In Vivo PDX Models
To learn more about our PDX model offerings, including molecular information, visit our Tumor Model Compendium.
Frequently Asked Questions (FAQs) in PDX Model Research
What is a patient-derived xenograft?
Patient-derived xenografts (PDX) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immune deficient or humanized mouse. PDX models simulate human tumor biology allowing for natural cancer progression, and offer the most translational research model for evaluating efficacy.
Determine which PDX model is best for your studies
Does in vitro data correlate with in vivo PDX models?
Data collected in in vitro models can be used to select PDX models for subsequent in vivo efficacy studies. Review the data
What oncology models are right for me?
In a complex and changing field, knowing the next step can be difficult. Answer a few brief questions about your research to receive expert guidance on how to advance your oncology program. Receive personalized advice
What is the latest oncology news?
Charles River’s Oncology Fast 5, is a scientist-curated skim of industry articles, blog posts, data, and interactive content covering hot topics in cancer research. Our digest will be delivered to your inbox once a month. Sign up today.